ME03537B - - Google Patents

Info

Publication number
ME03537B
ME03537B MEP2019272A ME03537B ME 03537 B ME03537 B ME 03537B ME P2019272 A MEP2019272 A ME P2019272A ME 03537 B ME03537 B ME 03537B
Authority
ME
Montenegro
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45998616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03537(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ME03537B publication Critical patent/ME03537B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/22—Heating, cooling or ventilating devices the heat source being other than the propulsion plant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/3228—Cooling devices using compression characterised by refrigerant circuit configurations
    • B60H1/32281—Cooling devices using compression characterised by refrigerant circuit configurations comprising a single secondary circuit, e.g. at evaporator or condenser side
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/323—Cooling devices using compression characterised by comprising auxiliary or multiple systems, e.g. plurality of evaporators, or by involving auxiliary cooling devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/00642—Control systems or circuits; Control members or indication devices for heating, cooling or ventilating devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/00192—Distribution of conditionned air to left and right part of passenger compartment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/002—Distribution of conditionned air to front and rear part of passenger compartment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mechanical Engineering (AREA)
  • Thermal Sciences (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
MEP2019272 2011-02-25 2012-02-24 ME03537B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446895P 2011-02-25 2011-02-25
US201161497650P 2011-06-16 2011-06-16
US201261595200P 2012-02-06 2012-02-06

Publications (1)

Publication Number Publication Date
ME03537B true ME03537B (sr) 2020-04-20

Family

ID=45998616

Family Applications (3)

Application Number Title Priority Date Filing Date
MEP2019272 ME03537B (sr) 2011-02-25 2012-02-24
MEP-2020-41A ME03732B (me) 2011-02-25 2012-02-24 Miševi s ADAM6
MEP-2015-35A ME02106B (me) 2011-02-25 2012-02-24 Miševi sa adam6

Family Applications After (2)

Application Number Title Priority Date Filing Date
MEP-2020-41A ME03732B (me) 2011-02-25 2012-02-24 Miševi s ADAM6
MEP-2015-35A ME02106B (me) 2011-02-25 2012-02-24 Miševi sa adam6

Country Status (31)

Country Link
US (12) US8642835B2 (sr)
EP (7) EP2578688B2 (sr)
JP (8) JP2014507137A (sr)
KR (1) KR101387377B1 (sr)
CN (2) CN105861548B (sr)
AU (6) AU2012243291B2 (sr)
BR (1) BR112013021771B1 (sr)
CA (1) CA2820824A1 (sr)
CY (5) CY1116301T1 (sr)
DE (5) DE12716101T1 (sr)
DK (6) DK2738259T3 (sr)
ES (6) ES2946169T3 (sr)
FI (3) FI2738258T4 (sr)
HR (5) HRP20150262T1 (sr)
HU (5) HUE046746T2 (sr)
IL (4) IL226727A (sr)
IN (1) IN2013CN07629A (sr)
LT (4) LT2578688T (sr)
ME (3) ME03537B (sr)
MX (3) MX343009B (sr)
MY (1) MY172713A (sr)
NZ (2) NZ776770A (sr)
PL (5) PL2738259T3 (sr)
PT (5) PT4067496T (sr)
RS (5) RS59413B2 (sr)
RU (2) RU2582261C2 (sr)
SG (4) SG10201405135RA (sr)
SI (5) SI4067496T1 (sr)
SM (5) SMT201900744T1 (sr)
WO (1) WO2012141798A1 (sr)
ZA (1) ZA201305998B (sr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
PL1776383T3 (pl) 2004-07-22 2015-02-27 Univ Erasmus Med Ct Rotterdam Cząsteczki wiążące
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
DK3028565T3 (da) 2009-07-08 2017-11-13 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
MX2012009168A (es) 2010-02-08 2012-08-31 Regeneron Pharma Raton de cadena ligera comun.
EP2947151A1 (en) 2010-08-02 2015-11-25 Regeneron Pharmaceuticals, Inc. Binding proteins comprising vl domains
EP2578688B2 (en) 2011-02-25 2023-02-08 Regeneron Pharmaceuticals, Inc. ADAM6 mice
AU2012279018B2 (en) 2011-07-05 2017-06-08 Children's Medical Center Corporation N-terminal deleted GP120 immunogens
HRP20241480T1 (hr) 2011-08-05 2025-01-03 Regeneron Pharmaceuticals, Inc. Humanizirani miševi univerzalnog lakog lanca
EP3741862A1 (en) 2011-09-19 2020-11-25 Kymab Limited Animals, repertoires & methods for the production of human antibodies
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
WO2013052095A2 (en) 2011-10-03 2013-04-11 Duke University Vaccine
PT3216871T (pt) 2011-10-17 2022-03-15 Regeneron Pharma Ratos com cadeia pesada de imunoglobulina restrita
US20180295821A1 (en) * 2011-12-02 2018-10-18 Kymab Limited Transgenic Animals
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG11201403326VA (en) 2011-12-20 2014-07-30 Regeneron Pharma Humanized light chain mice
NZ793447A (en) * 2012-02-01 2024-05-31 Regeneron Pharma Humanized rodents that express heavy chains containing vl domains
KR102213535B1 (ko) 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
RU2014141536A (ru) 2012-03-16 2016-05-10 Регенерон Фармасьютикалз, Инк. Мыши, которые продуцируют антигенсвязывающие белки с зависимыми от величины ph характеристиками связывания
ES2849349T3 (es) 2012-03-16 2021-08-17 Regeneron Pharma Anticuerpos de cadena ligera modificados mediante ingeniería con histidina y roedores modificados genéticamente para la generación de los mismos
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
CN107383197B (zh) 2012-04-20 2021-12-10 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
DK2858487T3 (da) 2012-06-12 2020-01-20 Regeneron Pharma Humaniserede ikke-humane dyr med begrænsede immunoglobulin-tungkæde-loci
RU2664187C2 (ru) 2013-02-06 2018-08-15 Регенерон Фармасьютикалз, Инк. Разработка иммуногена на основе в-клеточной линии дифференцировки с использованием гуманизированных животных
CN109769752A (zh) 2013-02-20 2019-05-21 瑞泽恩制药公司 具有修饰的免疫球蛋白重链序列的非人类动物
US9980470B2 (en) * 2013-03-14 2018-05-29 Erasmus University Medical Center Antibody production
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) * 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
SG11201602236SA (en) 2013-10-01 2016-04-28 Kymab Ltd Animal models and therapeutic molecules
JP6267986B2 (ja) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法
RU2016141123A (ru) 2014-03-21 2018-04-23 Регенерон Фармасьютикалз, Инк. Антигенсвязывающие белки vl, проявляющие различные связывающие характеристики
RU2016141307A (ru) * 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
EP3193592A1 (en) 2014-09-19 2017-07-26 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
HK1250038A1 (zh) 2015-03-19 2018-11-23 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
TWI752920B (zh) 2015-10-12 2022-01-21 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
CN114128676A (zh) * 2016-01-13 2022-03-04 瑞泽恩制药公司 具有包括改造的多样性簇的免疫球蛋白重链可变区的非人动物及其用途
WO2017143062A1 (en) 2016-02-16 2017-08-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
US20170332610A1 (en) * 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
US10980221B2 (en) 2016-06-03 2021-04-20 Regeneron Pharmaceuticals, Inc. Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
SG10201913483XA (en) 2016-11-04 2020-03-30 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain locus
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
WO2018226861A1 (en) 2017-06-07 2018-12-13 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
RS63772B1 (sr) 2017-12-05 2022-12-30 Regeneron Pharma Miševi koji imaju modifikovani lambda laki lanac imunoglobulina i njihove upotrebe
CA3090519A1 (en) 2018-02-07 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
AU2019237926B2 (en) 2018-03-21 2025-08-14 Crystal Bioscience Inc. Transgenic chicken that produces human antibodies
CA3093995A1 (en) 2018-03-24 2019-10-03 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
SG11202008620VA (en) 2018-03-26 2020-10-29 Regeneron Pharma Humanized rodents for testing therapeutic agents
AU2019249273B2 (en) 2018-04-06 2026-02-05 Regeneron Pharmaceuticals, Inc. Methods of treatment using a leptin receptor agonist antibody
KR20250140631A (ko) 2018-05-17 2025-09-25 리제너론 파마슈티칼스 인코포레이티드 항-cd63 항체, 콘쥬게이트, 및 이의 용도
WO2019240999A1 (en) * 2018-06-13 2019-12-19 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
JP7670627B2 (ja) 2019-02-18 2025-04-30 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド ヒト化免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
AU2020226865A1 (en) 2019-02-22 2021-07-29 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
EP3979790A1 (en) 2019-06-05 2022-04-13 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
EP3785536B2 (en) * 2019-08-28 2025-09-17 Trianni, Inc. Adam6 knockin mice
CN114901678A (zh) 2019-12-02 2022-08-12 瑞泽恩制药公司 肽-mhc ii蛋白构建体及其用途
CA3182925A1 (en) 2020-06-02 2021-12-09 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
CA3187680A1 (en) 2020-09-11 2022-03-17 Yashu Liu Identification and production of antigen-specific antibodies
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
IL303865A (en) 2020-12-23 2023-08-01 Regeneron Pharma Methods for obtaining antibodies that bind transmembrane proteins and cells that produce them
TW202241934A (zh) 2020-12-23 2022-11-01 美商再生元醫藥公司 編碼錨定修飾抗體之核酸及其用途
AU2022261074A1 (en) 2021-04-20 2023-09-28 Regeneron Pharmaceuticals, Inc. Human antibodies to artemin and methods of use thereof
MA71452A (fr) 2022-07-12 2025-04-30 Regeneron Pharmaceuticals, Inc. Anticorps dirigés contre le récepteur du facteur neurotrophique ciliaire (cntfr) et leurs procédés d'utilisation
CN120677178A (zh) 2023-02-13 2025-09-19 瑞泽恩制药公司 用抗人cacng1抗体治疗肌肉相关病症
AU2024265507A1 (en) 2023-05-02 2025-10-30 Regeneron Pharmaceuticals, Inc. Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
CN121568720A (zh) 2023-07-10 2026-02-24 瑞泽恩制药公司 抗人类cacng1抗体-药物缀合物及其用途
WO2025055311A1 (zh) 2023-09-15 2025-03-20 赛业（苏州）生物科技有限公司 用于制备抗体的基因修饰小鼠及其制备方法
EP4548758A4 (en) * 2023-09-15 2025-11-19 Cyagen Biosciences Suzhou Inc Genetically modified mice for antibody preparation and the method of preparation
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof
WO2025145264A1 (zh) * 2024-01-02 2025-07-10 江苏集萃药康生物科技股份有限公司 产生人源化抗体的动物模型及其构建方法
WO2026006724A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Prame off-target peptides and uses thereof
WO2026006734A1 (en) 2024-06-28 2026-01-02 Regeneron Pharmaceuticals, Inc. Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JPH08503617A (ja) * 1992-12-01 1996-04-23 プロテイン デザイン ラブズ、インコーポレーテッド Ｌ−セレクチンに反応性のヒト化抗体
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
CN1203922A (zh) * 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
RU10506U1 (ru) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич Ручной культиватор
CA2373638A1 (en) * 1999-05-27 2000-12-07 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
KR100583331B1 (ko) 2001-05-11 2006-05-26 기린 비루 가부시키가이샤 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체 및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는 비인간 동물
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
US20030108925A1 (en) 2001-10-05 2003-06-12 U.S. Epa Genetic testing for male factor infertility
JP4099646B2 (ja) 2002-06-04 2008-06-11 株式会社安川電機 ボイスコイルモータ
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
ES2318384T3 (es) 2005-06-30 2009-05-01 Borealis Technology Oy Capa exterior de funda para cables de potencia o de comuniccion.
CA2638774C (en) * 2006-03-31 2015-11-24 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
DK2374818T3 (da) 2006-06-02 2013-01-21 Regeneron Pharma Højaffinitetsantistoffer mod human IL-6-receptor
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
KR102362774B1 (ko) 2008-09-30 2022-02-15 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
CN112680475B (zh) * 2008-12-18 2024-11-12 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5399140B2 (ja) * 2009-06-18 2014-01-29 株式会社タイトー モールス信号通信システム
DK3028565T3 (da) 2009-07-08 2017-11-13 Kymab Ltd Dyremodeller og terapeutiske molekyler
PL2954779T3 (pl) 2009-12-10 2019-07-31 Regeneron Pharmaceuticals, Inc. Myszy wytwarzające przeciwciała ciężkołańcuchowe
MX2012009168A (es) 2010-02-08 2012-08-31 Regeneron Pharma Raton de cadena ligera comun.
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
AU2011266843C9 (en) 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
EP2578688B2 (en) 2011-02-25 2023-02-08 Regeneron Pharmaceuticals, Inc. ADAM6 mice
HRP20241480T1 (hr) 2011-08-05 2025-01-03 Regeneron Pharmaceuticals, Inc. Humanizirani miševi univerzalnog lakog lanca
PT3216871T (pt) 2011-10-17 2022-03-15 Regeneron Pharma Ratos com cadeia pesada de imunoglobulina restrita
GB201118579D0 (en) 2011-10-27 2011-12-07 Micromass Ltd Control of ion populations
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG11201403326VA (en) 2011-12-20 2014-07-30 Regeneron Pharma Humanized light chain mice
DK2858487T3 (da) 2012-06-12 2020-01-20 Regeneron Pharma Humaniserede ikke-humane dyr med begrænsede immunoglobulin-tungkæde-loci

Also Published As

Publication number Publication date
CY1116301T1 (el) 2017-02-08
DK4067496T5 (da) 2024-07-22
ME03732B (me) 2021-01-20
JP2025032218A (ja) 2025-03-11
LT2578688T (lt) 2019-11-11
JP5866127B2 (ja) 2016-02-17
ZA201305998B (en) 2016-07-27
PT2738258T (pt) 2019-12-10
US9944716B2 (en) 2018-04-17
US8697940B2 (en) 2014-04-15
US20150210776A1 (en) 2015-07-30
IL273986A (en) 2020-05-31
US9932408B2 (en) 2018-04-03
HRP20192311T1 (hr) 2020-03-20
AU2012243291B2 (en) 2015-07-09
ES2748832T3 (es) 2020-03-18
SG10201913155QA (en) 2020-02-27
PL4067496T3 (pl) 2023-07-31
SG10201913160QA (en) 2020-03-30
ES2748832T5 (es) 2023-06-08
IL261243A (en) 2018-10-31
EP2813573B1 (en) 2020-04-22
HUE047687T2 (hu) 2020-05-28
RS59929B1 (sr) 2020-03-31
EP2738259B1 (en) 2019-11-27
RU2582261C2 (ru) 2016-04-20
CY1122205T1 (el) 2020-11-25
EP2578688A1 (en) 2013-04-10
JP2014110814A (ja) 2014-06-19
US12207628B2 (en) 2025-01-28
DK2578688T4 (da) 2023-05-08
JP2019187446A (ja) 2019-10-31
HRP20200294T1 (hr) 2020-05-29
CN103429746B (zh) 2016-05-11
IL268671B (en) 2020-05-31
MX2020009714A (es) 2020-10-07
SMT201500061B (it) 2015-05-05
SG192933A1 (en) 2013-09-30
MX2013009649A (es) 2013-09-26
EP2813573A1 (en) 2014-12-17
HRP20191895T1 (hr) 2020-01-10
CN103429746A (zh) 2013-12-04
KR101387377B1 (ko) 2014-04-21
FI2738258T4 (fi) 2023-05-05
FI4067496T3 (fi) 2023-05-24
US8642835B2 (en) 2014-02-04
NZ797720A (en) 2024-09-27
LT4067496T (lt) 2023-06-12
JP2022071051A (ja) 2022-05-13
SMT201900581T1 (it) 2019-11-13
IL261243B (en) 2019-08-29
HRP20230526T1 (hr) 2023-09-01
AU2022206806A1 (en) 2022-08-18
NZ776770A (en) 2023-03-31
KR20130116375A (ko) 2013-10-23
US20180362663A1 (en) 2018-12-20
EP2578688B1 (en) 2019-07-24
PL2738258T5 (pl) 2023-05-15
SI2550363T1 (sl) 2015-04-30
ES2805364T3 (es) 2021-02-11
SI2738259T1 (sl) 2020-06-30
IL273986B (en) 2021-04-29
HUE062552T2 (hu) 2023-11-28
CY1122459T1 (el) 2021-01-27
SG10201405135RA (en) 2014-10-30
US20180345760A1 (en) 2018-12-06
EP2738259A2 (en) 2014-06-04
DK4067496T3 (da) 2023-06-26
IN2013CN07629A (sr) 2015-08-07
EP2550363A1 (en) 2013-01-30
DE14154967T1 (de) 2014-08-28
PL2738259T3 (pl) 2020-08-24
PT4067496T (pt) 2023-06-07
US20210105985A1 (en) 2021-04-15
DK2578688T1 (da) 2014-11-24
EP2738258A3 (en) 2014-09-24
ES2758974T3 (es) 2020-05-07
HUE046081T2 (hu) 2020-01-28
RS59413B1 (sr) 2019-11-29
PL2738258T3 (pl) 2020-08-24
MY172713A (en) 2019-12-11
AU2025283466A1 (en) 2026-01-22
SMT202300173T1 (it) 2023-07-20
US20130254911A1 (en) 2013-09-26
AU2020201279A1 (en) 2020-03-12
IL268671A (en) 2019-10-31
EP2578688B2 (en) 2023-02-08
IL226727A (en) 2016-08-31
DE12192727T1 (de) 2013-07-11
DK2813573T1 (da) 2015-01-12
HUE024534T2 (hu) 2016-01-28
SMT201900744T1 (it) 2020-01-14
EP2738258B2 (en) 2023-02-01
PL2550363T3 (pl) 2015-05-29
JP2016135143A (ja) 2016-07-28
ES2770424T3 (es) 2020-07-01
US20180346598A1 (en) 2018-12-06
JP2014507137A (ja) 2014-03-27
LT2738258T (lt) 2020-01-10
EP2738258A2 (en) 2014-06-04
AU2017251802A1 (en) 2017-11-16
MX343009B (es) 2016-10-21
RU2016109443A (ru) 2018-11-26
ES2532487T3 (es) 2015-03-27
CN105861548A (zh) 2016-08-17
RS59413B2 (sr) 2023-06-30
EP2738259A3 (en) 2014-07-30
LT2738259T (lt) 2020-03-10
DE12716101T1 (de) 2013-05-08
DK2738259T3 (da) 2020-02-17
JP2015107131A (ja) 2015-06-11
HRP20150262T1 (hr) 2015-04-10
EP2738258B1 (en) 2019-09-25
AU2022206806B2 (en) 2025-10-02
RS64280B1 (sr) 2023-07-31
SI2738258T1 (sl) 2020-01-31
CN105861548B (zh) 2020-01-10
JP2018143250A (ja) 2018-09-20
SI2578688T2 (sl) 2023-05-31
MX375115B (es) 2025-03-06
US10905109B2 (en) 2021-02-02
DE14154918T1 (de) 2014-08-21
DK2738258T1 (da) 2014-11-24
BR112013021771A2 (pt) 2017-07-04
DK2550363T3 (en) 2015-03-23
SI2738258T2 (sl) 2023-05-31
PL2578688T5 (pl) 2023-05-29
EP4067496B1 (en) 2023-03-29
AU2015238806A1 (en) 2015-10-29
RS59661B2 (sr) 2023-06-30
EP2550363B1 (en) 2014-12-10
HK1201292A1 (en) 2015-08-28
BR112013021771B1 (pt) 2022-11-16
ME02106B (me) 2015-10-20
NZ612643A (en) 2015-06-26
PT2550363E (pt) 2015-03-16
US10905108B2 (en) 2021-02-02
HUE046746T2 (hu) 2020-03-30
RS53880B1 (sr) 2015-08-31
RU2016109443A3 (sr) 2019-07-24
FI2578688T4 (fi) 2023-05-05
US20210105984A1 (en) 2021-04-15
HRP20192311T4 (hr) 2023-05-12
US20140213773A1 (en) 2014-07-31
SI2578688T1 (sl) 2019-11-29
DK2738258T4 (da) 2023-05-08
US10577430B2 (en) 2020-03-03
US20240306617A1 (en) 2024-09-19
SI4067496T1 (sl) 2023-07-31
DE14176593T1 (de) 2015-03-05
EP3744850A1 (en) 2020-12-02
RS59661B1 (sr) 2020-01-31
CY1126091T1 (el) 2023-11-15
HRP20191895T4 (hr) 2023-05-12
RU2013125717A (ru) 2014-12-10
US10694725B2 (en) 2020-06-30
AU2012243291A1 (en) 2013-05-09
DK2578688T3 (da) 2019-10-28
CA2820824A1 (en) 2012-10-18
PT2578688T (pt) 2019-10-24
US11950578B2 (en) 2024-04-09
RU2722373C2 (ru) 2020-05-29
NZ731926A (en) 2021-07-30
HK1174490A1 (en) 2013-06-14
CY1122820T1 (el) 2021-05-05
PT2738259T (pt) 2020-02-18
US20150201589A1 (en) 2015-07-23
PL2578688T3 (pl) 2020-05-18
DK2738259T1 (da) 2014-11-24
US20180346599A1 (en) 2018-12-06
SMT202000112T1 (it) 2020-05-08
NZ703609A (en) 2016-04-29
US10072095B2 (en) 2018-09-11
DK2738258T3 (da) 2019-12-16
US20120322108A1 (en) 2012-12-20
ES2946169T3 (es) 2023-07-13
WO2012141798A1 (en) 2012-10-18
NZ718688A (en) 2017-07-28
ES2758974T5 (es) 2023-06-08
EP4067496A1 (en) 2022-10-05

Similar Documents

Publication Publication Date Title
BR112013022641A2 (sr)
BR122020014038A2 (sr)
BR112013031251A2 (sr)
BR112013027245A2 (sr)
BR112013024383A2 (sr)
BR112013026905A2 (sr)
BR112013023185A2 (sr)
BR112013022995A2 (sr)
BR112013027830A2 (sr)
BR112013026744A2 (sr)
BR112013023927A2 (sr)
BR112013027452A2 (sr)
BR112013024365A2 (sr)
BR112013028733A2 (sr)
BR112013027121A2 (sr)
BR112013031556A2 (sr)
BR112013024588A2 (sr)
BR112013026790A2 (sr)
BR112013032368A2 (sr)
BR112013032380A2 (sr)
BR112013032377A2 (sr)
BR112013027836A2 (sr)
BR112013018949A2 (sr)
BR112013026895A2 (sr)
BR112013027761A2 (sr)